38 results about "Abnormal blood vessels" patented technology

The invention relates to an ischemic cerebrovascular disease angiography image segmentation analysis method, which comprises the following steps: detecting gray transition abnormity, structural fracture and artifact delay signals in an angiography image, extracting negative segmentation priori points indicating a suspected ischemic area, aggregating to form a priori abnormal area, introducing a symmetric disturbance test mechanism, and analyzing the angiography image according to the priori abnormal area. Judging a potential blocked or abnormal blood vessel segment, and dynamically adjusting the segmentation threshold of the region; establishing a local interference window in the judgment region, extracting frequency and rhythm features of density stripes, and performing compensation segmentation on interrupted blood vessel segments caused by unsteady pulse change through a convolution kernel scaling strategy; calculating a texture difference value and a frequency domain response offset, if the offset is within a preset physiological tolerance range, triggering an interpolation completion mechanism, and generating a credible completion layer for subsequent calibration reference; and performing dynamic feedback adjustment and continuous calibration on the previously segmented path by analyzing the multi-path divergence degree of the vascular branch end point and the path offset change in the image sequence.

Systems and methods for x-ray imaging a patient's breast in combinations of dual-energy, single-energy, mammography and tomosynthesis modes that facilitate screening for and diagnosis of breast abnormalities, particularly breast abnormalities characterized by abnormal vascularity.

The invention proves that the isosakuranetin can inhibit the generation of osteoclasts and the functions of the osteoclasts in vitro, protect the bone microstructure of subchondral bones of an OA (osteoarthritis) mouse, relieve the degeneration of articular cartilage of the OA mouse, inhibit the generation of abnormal blood vessels in subchondral marrow cavities in the progress of the OA, and inhibit the osteoclasts in the osteoclasts. The invention proves that the isosakuranetin has a treatment effect on the osteoarthritis for the first time, and discloses an action mechanism of the isosakuranetin.

The present invention demonstrates that isosakurabin can inhibit the formation and function of osteoclasts in vitro, protect the bone microstructure of the subchondral bone in mice with osteoarthritis (OA), reduce articular cartilage degeneration in OA mice, inhibit the formation of abnormal blood vessels in the subchondral bone marrow cavity during OA progression, and alleviate joint pain induced by abnormal osteoclast activation in OA mice. This invention demonstrates for the first time that isosakurabin has a therapeutic effect on osteoarthritis and reveals its mechanism of action.

To provide a novel therapeutic or prophylactic agent for abnormal angiogenesis and its applications.SOLUTION: A therapeutic or prophylactic agent for abnormal angiogenesis is used that contains a histone acetyltransferase inhibitor as an active ingredient.SELECTED DRAWING: None

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

This invention relates to a method for segmenting and analyzing angiographic images of ischemic cerebrovascular diseases. It detects abnormal grayscale transitions, structural breaks, and artifact delay signals in angiographic images, extracts negative prior points indicating suspected ischemic areas, aggregates them to form prior abnormal regions, introduces a symmetric perturbation testing mechanism to determine potential occluded or abnormal vascular segments, and dynamically adjusts the segmentation threshold of the region. A local interference window is established within the determined region, and the frequency and rhythmic features of density stripes are extracted. Through the scaling strategy of the convolution kernel, discontinuous vascular segments caused by non-steady-state pulse changes are compensated for segmentation. Texture difference and frequency domain response offset are calculated. If the offset is within a preset physiological tolerance range, an interpolation completion mechanism is triggered to generate a reliable completion layer for subsequent calibration reference. By analyzing the multipath divergence degree of the vascular branch endpoints and the path offset changes in the image sequence, the previously segmented paths are dynamically adjusted and their continuity is calibrated.

The invention relates to the technical field of image recognition processing, and provides a nail fold microcirculation imaging control and image recognition analysis method and system. Based on the scattering characteristic information of the imaging illumination light detection of the nail fold area, the attribute information of the illumination abnormal area is determined, and the illumination light projection modulation is performed; the nail fold area is image recognized, and the capillary image set of the target sub-area is obtained, so as to realize the directional image acquisition of the capillaries in the nail fold area; the vascular morphology is recognized for all the capillary images, the abnormal vascular parts therein are calibrated, and the abnormal vascular parts sub-image sets are obtained by classification, so as to reduce the recognition workload and the error recognition rate; the abnormal vascular parts sub-image set is subjected to time evolution analysis, and the blood circulation characteristic information is obtained, so as to generate the microcirculation model of the nail fold area, realize the global microcirculation characterization of the nail fold area, predict the abnormal microcirculation evolution result, comprehensively and correctly reflect the real microcirculation state of the nail fold area, and improve the credibility of the nail fold microcirculation recognition.

The invention provides a smoke disease model and a construction method and application thereof, and belongs to the technical field of smoke disease model construction. The method for constructing the smog disease model comprises the following steps: extracting CD34 + hematopoietic progenitor cells in peripheral blood of a smog disease patient, reprogramming to generate hiPSC, further differentiating into brain organs and vascular organs, fusing the brain organs and the vascular organs, and culturing and constructing the vascularized brain organ smog disease model. The smoke disease model constructed by adopting the construction method disclosed by the invention can simulate and reproduce phenotypes such as tiny branch increase, macrovascularization, pericytopenia, smooth muscle fibrosis deposition, abnormal angiogenesis increase and the like in clinical core pathological phenotypes of smoke disease patients, and is superior to existing animal and cell models to a certain extent.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

The invention discloses a special AI auxiliary device for fundus blood vessel anomaly detection, which comprises a base, a system terminal, a stand column, a lifting assembly, an anti-blink assembly, a sliding assembly, a cleaning assembly and a pressure assembly, and is characterized in that the system terminal is fixedly mounted on the base. Through an anti-blink assembly, after two curved groove blocks slide to the two ends of a hyperbolic rod respectively, a patient attaches the eyebrow bone to a gap in the hyperbolic rod, wears an elastic strap on the head, attaches an air support to the jaw through a lifting assembly, and then screws a second lead screw to enable a trapezoidal block to slide backwards, at the moment, the cambered surface of the support block descends along the inclined surface of the trapezoidal block, and the air support is fixed to the upper portion of the hyperbolic rod. When the head of a patient descends along with the air support, the double curved bars keep the eyelids at the eyebrow bones still, the downward movement of the head and the fixation of the double curved bars form relative displacement, so that the upper eyelids are stably pulled up, the eyelids are kept at the eye opening amplitude, the upper eyelids are prevented from naturally drooping or reflexively closing, and imaging missing or blurring caused by blinking and eyelid drooping is avoided; and the AI detection data is ensured to be complete and effective.

The invention provides a prediction tool for auxiliary diagnosis of coronary heart disease through combination of traditional Chinese medicine and western medicine and a score table, particularly relates to a coronary heart disease noninvasive auxiliary diagnosis score table based on four diagnosis information of traditional Chinese medicine, and belongs to the technical field of medical diagnosis. The method focuses on a non-invasive prediction model of the coronary heart disease for the first time, and solves the problems of strong invasiveness and unintegration of traditional Chinese medicine characteristics in the prior art. Core predictive variables are screened by collecting four diagnosis information (including intraocular angular blood vessel thickening, blood stasis expression and other traditional Chinese medicine sign characteristic clinical expressions) of coronary heart disease patients, and a Logistic regression model is constructed and converted into a score table. The scale comprises indexes such as age, combined diseases, typical angina pectoris, abnormal angular blood collaterals in eyes, blood stasis and kidney deficiency, and the coronary heart disease is diagnosed when the total score is greater than or equal to 4. According to the method, the model for predicting the coronary heart disease is constructed by utilizing a statistical method, and the model is converted into the score table which is easy to operate through the statistical method, so that clinical popularization and application are facilitated, doctors are assisted to make accurate and efficient clinical decisions, and clinical doctors are guided to make accurate and effective treatment schemes.

To provide peptide compositions and methods for inhibiting neovascularization or development of pathogenic or aberrant blood vessels in human or other animal subjects.SOLUTION: Provided herein is a composition comprising a peptide consisting of an amino acid sequence of Gly-Arg-Gly-Cys-Thr-Pro. The composition is administered to a human or animal subject for inhibiting neovascularization or development of pathogenic or aberrant blood vessel in a therapeutically effective amount. The composition is also administered to the eye of a subject with neovascularization or development of pathogenic or aberrant blood vessels to treat the eye disease or disorder of the subject.SELECTED DRAWING: Figure 5

The application belongs to the technical field of medical devices, and relates to an intelligent puncture sheath. The intelligent puncture sheath comprises a puncture sheath main body, a puncture monitoring structure and a blood vessel processing structure. The blood vessel processing structure comprises a retractable suction cup, a suction cup position control module, a clamping control module and a medicine capsule. The retractable suction cup is more than two and is connected to the suction cup position control module. The suction cup position control module can control the retractable suction cup to move below a blood vessel tear. The retractable suction cup comprises a suction cup and a suction cup telescopic rod. The suction cup can be controlled to contact the blood vessel wall through telescopic operation and is adsorbed on the blood vessel wall through negative pressure. The clamping control module can control the suction cups adsorbed on both ends of the blood vessel tear to perform closing operation to clamp the blood vessel tear. The medicine capsule can quantitatively spray medicine to the blood vessel tear to promote further healing of the blood vessel. The application is especially suitable for special groups of people with abnormal blood vessel structure.

The application provides a blood vessel center line correction method and device, a storage medium and equipment. The method is applied to the technical field of blood vessel center line extraction. The method obtains an abnormal blood vessel mask area in a target blood vessel based on a blood vessel reconstruction view of the target blood vessel, performs abnormal type determination based on morphological features of the abnormal blood vessel mask area, and then corrects the abnormal center line of the abnormal blood vessel mask area based on a corresponding correction strategy. After the initial center line extraction of the blood vessel, the method increases the blood vessel abnormality determination process, assigns different correction strategies to different abnormal types, and corrects the abnormal center line caused by the blood vessel abnormality in a targeted manner, thereby improving the efficiency of the center line correction and the accuracy of the center line extraction.

The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.

To provide a novel therapeutic or prophylactic agent for abnormal angiogenesis, and its applications.SOLUTION: A therapeutic or prophylactic agent for abnormal angiogenesis is used that contains a lysine demethylase 3A inhibitor as an active ingredient.SELECTED DRAWING: None

The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of a human immunoglobulin G (IgG) (in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). Further, the present invention relates to a composition for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused, and to a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.

The invention relates to the technical field of biological medicine, in particular to ureido indolone compounds and a preparation method and application thereof. Compared with the prior art, the ureido indolone compound provided by the invention has the advantages that the activity of VEGFR, PDGFR and / or FGFR can be effectively inhibited, signal transduction of VEGF, PDGF and / or FGF is blocked, and systemic neovascularization (abnormal vascular hyperplasia) related diseases are treated.

The present invention discloses compounds according to Formula I:wherein R1, R2a, W, X1, X2, Y and Z are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

The invention relates to the technical field of preparation of targeted nanoparticles and gel materials, and discloses a nanoparticle hydrogel spray containing targeted NRP1 as well as a preparation method and application of the nanoparticle hydrogel spray, the nanoparticle is of a core-shell structure, polydopamine is taken as a carrier material, the core is obtained by connecting Tat-C-RP7 and PDA-NPs through a Schiff base reaction, and the shell is ZIF8. The preparation method of the hydrogel spray comprises the following steps: step 1, synthesis of nanoparticles: synthesizing PDA-TCR7-ZIF8-NPs by a three-step method; and step 2, preparation of hydrogel spray: resuspending the PDA-TCR7-ZIF8-NPs in a beta-sodium glycerophosphate solution, and uniformly mixing and stirring the PDA-TCR7-ZIF8-CS (at) GP hydrogel solution with a chitosan solution under an ice-water bath condition, so as to obtain a PDA-TCR7-ZIF8-CS (at) GP hydrogel solution. The nano hydrogel can accurately target NRP1, and can reduce the scar area by 60% and the skin thickness from 1.8 mm to 1.1 mm in animal experiments aiming at the key vascular abnormality generation and fibrosis mechanism for scar formation, and can improve the scar color and flatness.

The invention relates to temperature-sensitive hydrogel and a preparation method thereof, and belongs to the technical field of temperature-sensitive hydrogel. The preparation method of the thermo-sensitive hydrogel comprises the following steps: carrying out hydroxyl protection on hydroxybutyl chitosan, carrying out hydroxylation modification on amino sites, grafting a chain transfer agent by using the modified hydroxyl, carrying out graft copolymerization on a wet adhesive functional monomer with a phenolic hydroxyl protective agent by using the chain transfer agent, and finally removing a hydrophobic end group of the chain transfer agent to obtain the thermo-sensitive hydrogel. The temperature-sensitive hydrogel with excellent adhesiveness, injectability and temperature-sensitive characteristic is obtained by adding the hydrogel, the phenolic hydroxyl protective agent and the hydroxyl protective agent, the material can effectively block abnormal blood vessels after being injected into a human body, and due to the good wet-state adhesion performance and embolism performance, the temperature-sensitive hydrogel can be used for blocking the abnormal blood vessels. The probability that residual fragments are formed due to blood flow impact in the blood vessel embolism process and the probability that blood vessels are re-opened due to blood flow impact after embolism can be effectively reduced.

The invention relates to the technical field of microorganisms, in particular to an application of clostridium praeparatum and / or ackermann mucilaophilum. The invention provides an application of clostridium praeckii and / or Ackermann mucilaophilum in inhibition of inflammatory response and neovascularization after body injury, and provides a non-drug and probiotic biological treatment method based on clostridium praeckii and Ackermann mucilaophilum, and the application of clostridium praeckii and Ackermann mucilaophilum in inhibition of inflammatory response and neovascularization after body injury. The invention aims to provide a new solution for inflammatory response and abnormal angiogenesis problems in body injury (such as retinopathy, retinal detachment and the like).

An imaging system includes a camera, a display, and a processor. The camera has color video acquisition capability and is mounted to the distal end of an interventional instrument that can be inserted into an object, the camera providing image frames for imaging the vascular system of the object, each image frame including a plurality of pixels providing corresponding signals. The processor is programmed to: receive signals; amplify changes in at least one of color and motion of the signals corresponding to the plurality of pixels; respectively determine spatial phase variability, frequency, and signal characteristics of at least some of the amplified signals corresponding to the plurality of pixels; identify pixels indicating abnormal vascular distribution based on spatial phase variability, frequency, and / or signal characteristics; create a vascular map corresponding to each, wherein each vascular distribution map includes a portion of the object having abnormal vascular distribution; and operate the display to display each vascular distribution map.

The present invention achieves: a compound having lysine demethylase 3A inhibitory activity; a lysine demethylase 3A inhibitor containing the compound; and a therapeutic or prophylactic agent for abnormal angiogenesis containing the lysine demethylase 3A inhibitor. An azide-alkyne conjugate having a specific structure is used as an active ingredient of the lysine demethylase 3A inhibitor, or the therapeutic or prophylactic agent for abnormal angiogenesis.

Systems and methods are disclosed herein for providing guidance and feedback during an operation during a vascular intervention by Doppler ultrasound during the operation on one or more distal peripheral vessels affected by the vascular intervention. In accordance with various exemplary embodiments, Doppler ultrasound is performed during operation to detect flow characteristic changes and / or abnormal vascular flow characteristics of the interventional-affected peripheral vascular system, such as detection of adverse vascular events. The detected blood flow characteristic changes are communicated during operation to guide and / or assist in clinical decisions, and / or are used to automatically send control signals to interrupt or adjust treatment. In other embodiments, guidance and / or feedback during the operation is automatically provided during the neuromodulation operation via Doppler ultrasound of one or more peripheral vessels whose blood flow is modulated by the neuromodulation operation, and the neuromodulation device may be optionally controlled based on detected changes in blood flow.

The present invention discloses compounds according to Formula (I) wherein X1, X2, Y, R1, L1, R 2, R 3, Cy and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12, IL-17 and / or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering a compound of the invention.

This application discloses a multispecific fusion protein comprising a binding construct that targets and is capable of binding to at least one of DLL4 and VEGF family members; or an antigen-binding fragment or domain thereof. This application also discloses a multispecific fusion protein comprising an antibody against DLL4 or an antigen-binding fragment thereof, multiple extracellular domains of the VEGF receptor or an antibody against at least one VEGF family member or an antigen-binding fragment thereof, and an antibody or binding peptide against Ang-2. The multispecific fusion protein can be used to treat or control ocular or systemic diseases, conditions, or disorders caused by abnormal angiogenesis, increased vascular leakage, inflammation, fibrosis, or combinations thereof.

The invention provides a blood vessel deformity degree evaluation method based on confocal endoscope imaging hemodynamic parameters, and relates to the technical field of artificial intelligence medical treatment, the method comprises two stages: imaging stable stage screening: collecting a blood vessel examination video through a confocal laser microendoscope; screening out image stable fragments in the blood vessel examination video according to dynamic change and velocity dynamics characteristics of red blood cells in the blood vessel; and malformation blood vessel evaluation: performing video frame extraction processing on the image stable segment to obtain multiple frames of images, analyzing the blood vessel malformation condition in each frame of image in combination with haemodynamic parameters and blood vessel morphology, labeling the blood vessel malformation segment, quantifying the malformation degree of the blood vessel malformation segment, and evaluating the blood vessel malformation. According to the method provided by the invention, the blood vessel abnormality is evaluated by combining the hemodynamic parameters and the blood vessel morphology, and the efficiency and accuracy of blood vessel abnormality detection can be effectively improved.

The invention relates to the technical field of biological medicine, in particular to a quinoline indolone compound and a preparation method and application thereof. The quinoline indolone compound has the advantages that the quinoline indolone compound provided by the invention can be used for treating diseases caused by abnormal vascular hyperplasia.